We DesignWe apply our unique collective expertise to design small molecule therapeutics. BreakthroughWe push the leading edge to solve drug discovery’s big challenges. MedicinesWe strive to develop meaningful medicines for patients.
Over more than a decade of pioneering technologically-driven methods of drug discovery, Nimbus has used cutting-edge tools to make therapeutic progress against the most challenging of targets — successfully drugging the undruggable, mapping the uncrystallizable and advancing multiple innovative therapeutics to the clinic.
Chief Medical Officer & President of Tyk2 Subsidiary
Senior Vice President of Preclinical Development
Chief People Officer
Senior Vice President, Head of Chemistry
Chief Business Officer
Chief Executive Officer
Senior Vice President, Head of Biology
Chief Scientific Officer
Chief Financial Officer
Board of Directors
General Partner, Atlas VentureRead bio
General Partner, Lightstone VenturesRead bio
Analyst, RA Capital ManagementRead bio
Partner, SR One Ltd.Read bio
General Partner, Lilly VenturesRead bio
Chairman and CEO, Kala PharmaceuticalsRead bio
Partner, Pfizer VenturesRead bio
CEO, Nimbus TherapeuticsRead bio
President and CSO, Navitor PharmaceuticalsRead bio
Nimbus Therapeutics is backed by world-class life science investors, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures, RA Capital and BVF Partners. The company closed a $24 million Series A financing in June 2011, a $43 million Series B financing in March 2015, an additional $65 million in financing in June 2018 and another $60 million in financing in October 2020.